Market Risk

Showing 4100 articles
Business

Brunswick Charts Steady Course as Marine Market Rebounds, Touts Record Cash Flow and Debt Reduction

Brunswick Corporation (NYSE: BC) closed its 2025 fiscal year on a confident note, citing a resilient recovery in the marine market, a historic surge in free cash flow, and significant debt reduction. While navigating persistent tariff headwinds, the company's leadership pointed to stabilizing retail demand and strategic market share gains as key drivers for cautious optimism heading into 2026.

Business

C4 Therapeutics: Can Its Protein-Degrading Tech Ignite a Biotech Rally?

Amid a challenging market for biotech, C4 Therapeutics (NASDAQ: CCCC) is drawing investor attention with its targeted protein degradation platform. Backed by industry giants and focused on niche cancers, the clinical-stage company presents a high-risk, high-reward proposition. We examine the bull case and the road ahead.